|
|
|
|
| LEADER |
01653 am a22002413u 4500 |
| 001 |
88032 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Poutahidis, Theofilos
|e author
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Division of Comparative Medicine
|e contributor
|
| 100 |
1 |
0 |
|a Erdman, Susan E.
|e contributor
|
| 100 |
1 |
0 |
|a Poutahidis, Theofilos
|e contributor
|
| 700 |
1 |
0 |
|a Kleinewietfeld, Markus
|e author
|
| 700 |
1 |
0 |
|a Erdman, Susan E.
|e author
|
| 245 |
0 |
0 |
|a Gut Microbiota and the Paradox of Cancer Immunotherapy
|
| 260 |
|
|
|b Frontiers Research Foundation,
|c 2014-06-19T18:32:51Z.
|
| 856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/88032
|
| 520 |
|
|
|a It is recently shown that beneficial environmental microbes stimulate integrated immune and neuroendocrine factors throughout the body, consequently modulating regulatory T-lymphocyte phenotypes, maintaining systemic immune balance, and determining the fate of preneoplastic lesions toward regression while sustaining whole body good health. Stimulated by a gut microbiota-centric systemic homeostasis hypothesis, we set out to explore the influence of the gut microbiome to explain the paradoxical roles of regulatory T-lymphocytes in cancer development and growth. This paradigm shift places cancer prevention and treatment into a new broader context of holobiont engineering to cultivate a tumor-suppressive macroenvironment.
|
| 520 |
|
|
|a National Institutes of Health (U.S.) (grant P30-ES002109)
|
| 520 |
|
|
|a National Institutes of Health (U.S.) (grant U01CA164337)
|
| 520 |
|
|
|a National Institutes of Health (U.S.) (grant RO1CA108854)
|
| 546 |
|
|
|a en_US
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t Frontiers in Immunology
|
